A new method for characterizing signaling responses to pairs of agonists predicts how cells react to higher-order combinations of external stimuli.
Platelet agonists mobilize calcium from intracellular stores to drive thrombosis. Calcium second-messenger dynamics are readily monitored by sensitive fluorescent dyes whose spectral properties change with the concentration of intracellular calcium. Chatterjee et al. 2 established a cell-based assay of intracellular calcium concentration with one such dye and used the assay to define the half-maximal effective concentration (EC 50 ) for six orthogonal platelet agonists. They then devised a high-throughput method for measuring the intracellular calcium concentration profile of a platelet suspension for 4 minutes after stimulation with all possible combinations of six agonists at 0.1 ×, 1 × or 10 × their EC 50 in a single 384-well plate (Fig. 1) . Notably, the resulting 135 stimulus pairs fell right where the combinatorics start to become unwieldy-for instance, it would take four times as many measurements to assay all stimulus triples.
In total, PAS experiments yielded tens of thousands of intracellular calcium concentration measurements for each platelet sample. The authors then extracted pairwise information from these data by defining a synergy score for the time-integrated intracellular calcium concentration response to agonist combinations. This score captures synergy, antagonism and additivity in a single metric and compresses each measurement into a 135-element synergy score vector that describes the synergy 'signature' for a platelet population.
Remarkably, when the authors applied PAS to platelets from ten human donors, they found that synergy signatures could reproducibly organize donors into subpopulations with greater fidelity than previous studies had reported. Such patient separation based on platelet phenotype has long been desired for predicting adverse reactions to coagulant, anticoagulant and thrombolytic drugs. To translate the applications of this work further toward patient prognosis, it will be important (e.g., A + B + C) would likely be too rare to evolve their own specific signal-integration mechanisms beyond those provided by subsets of two stimuli (e.g., A + B, B + C or A + C).
The work by Chatterjee et al. 2 and two other recent reports 6, 7 provide experimental support for this theoretical argument. Using different approaches, the three groups found that higher-order stimulus combinations could be accurately predicted from pairwise information. As emphasized in one study 6 , the practical implications of this finding are substantial, because it suggests that it is sufficient to test fewer stimulus cocktails experimentally. With existing high-throughput approaches 8 one should easily be able to quantify signaling responses to all pairwise combinations of 20-40 ligands that a cell type is most likely to encounter. Pairwise measurements could then enable data-driven predictions of any higherorder ligand combination as the need arises. These predictions could be incorporated into tissue-level models composed of multiple cell types and stimuli that vary in time and space. A comprehensive and predictive model of signal integration would also provide a means to search for cocktails that amplify desired signaling outputs or dampen undesirable ones.
The method of Chatterjee et al. 2 , called pairwise agonist scanning (PAS), systematically exploits the power of pairwise measurements to make network-specific predictions and diagnoses. The authors focused on the calcium response of platelets to agonists of blood clotting, or thrombosis. Understanding the environmental factors and intrinsic network properties that control platelet activation is of considerable clinical interest because too much or too little clotting can be fatal. Furthermore, as a model for signal trans duction, the platelet is ideal-no nucleus, a few thousand mRNA species and a collection of signaling proteins dedicated to one major function.
Cells process a multitude of external stimuli through receptor and adaptor proteins that converge on a core set of signal-transduction pathways 1 . How are such complex inputs converted into signaling outputs? In this issue, Chatterjee et al. 2 describe an experimentally tractable method for predicting signaling responses to the enormous number of stimulus 'cocktails' that a cell might encounter. Their test case is calcium signaling in platelets, but the approach holds promise for modeling signal integration in any cell.
If every signaling output were unique to an associated receptor, one could simply characterize signaling responses to individual stimuli and then use linear superposition to infer the global response to any stimulus combination. Of course, cross-talk in signaling is more the rule than the exception, and so merely focusing on individual inputs would overlook key network properties 3 . Nevertheless, cross-talk does not require one to test all stimulus combinations to reveal important features of signal transduction. Previous studies have shown that simple pairwise stimulation of cells can provide unique information about the activation states of a signaling network [3] [4] [5] . But it has remained unclear whether pairwise stimulation captures the major features of signal integration or whether higher-order combinations of three or more stimuli are necessary.
Cells almost certainly encounter complex stimulus combinations in their in vivo microenvironment. However, as the number of stimuli increases beyond two, the number of possible combinations quickly explodes, and the chance that a cell will see any particular higher-order combination becomes exceedingly small. Triple-stimulus combinations to connect PAS-based discrimination with key clinical variables or platelet aggregopathies.
PAS signatures may be reproducible and donor specific, but do they truly capture the higher-order signal-transduction properties of cells? To compile the PAS data in a format that enables predictions for new cocktails of agonists, Chatterjee et al. 2 used a history-dependent form of neural-network modeling 9 (Fig. 1) . With reasonably few fitted parameters, they built a model to predict the platelet intracellular calcium concentration time course, given an arbitrary combination and timing of the six selected agonists. When challenged with new cocktails added together or sequentially, the model performed surprisingly well. Overall, the authors observed a strong correlation between predicted and measured synergy scores, although predicted intracellular calcium concentration responses occasionally did not match experimental measurements when several agonists were added together at 10 × EC 50 . Importantly, the predictions were achieved using <4% of the data that would be required to measure the six-factor agonist space exhaustively. PAS efficiency would become even more dramatic if more agonists were included in the stimulus panel.
The utility of PAS should extend well beyond the particular network studied in this paper. For example, with proper signaling readouts, PAS could be used in pharmaceutical development to investigate the primary hits from a small-molecule screen. PAS in the presence and absence of a primary compound would quickly reveal contexts in which the drug has perturbed the normal signal-transduction machinery. Overall, PAS will be most successful in situations where the convergent intracellular pathways are established and where time-dependent signaling readouts are easily obtained for hundreds to thousands of samples. Skp1-Cul1-F-box protein (SCF) ligase-is composed of a central cullin scaffold that binds the RING domain-containing protein Rbx1 through its C terminus and the Skp1-F-box protein substrate receptor module on its N terminus 4 (Fig. 1a) . Rbx1 recruits the ubiquitincharged E2-conjugating enzyme Cdc34, which ubiquitinates substrates bound to the F-box protein. SCFs are thought to target hundreds of different substrates for ubiquitination through variants of the F-box protein, ~70 of which are present in the human genome. F-box proteins typically bind substrates through leucine-rich or WD40 repeats located near their C terminus, often in a phosphorylation-dependent manner. For example, through the WD40 repeats of Cdc4, SCF Cdc4 recognizes the Cdk1 inhibitor Sic1 once it is phosphorylated within multiple Cdc4 phosphodegron motifs 5, 6 . A degron is a small motif that is sufficient for the recruitment of and ligation of ubiquitin by an E3 ligase. The human Cdc4 ortholog Fbw7 is a tumor suppressor that targets several key cell cycle and transcriptional control proteins containing conserved Cdc4 phosphodegron motifs 7, 8 .
SCF complexes hold significant potential for therapeutic intervention from a biological perspective as they are linked to many disease processes. Nevertheless, they have proven challenging to target, in large part because the The ubiquitin-proteasome system for protein degradation regulates a wide array of cellular processes, and its misregulation has been linked to numerous human pathologies. General inhibitors of the proteasome and of the cullin-RING sub-family of E3 ubiquitin ligases that confer specificity to the ubiquitin machinery have shown promise against cancer in clinical and preclinical studies 1 , triggering a search for more discriminating drugs that might have greater efficacy and safety for particular indications. As described in this issue, Orlicky et al. 2 and Aghajan et al. 3 have now identified the first specific inhibitors of individual cullin-RING E3 ubiquitin ligases. Although these studies were carried out in budding yeast, they raise the exciting possibility of developing drugs targeting components of the human cullin-RING ligase system that were previously considered 'undruggable' . Moreover, Orlicky et al. 2 reveal what may emerge as a general strategy for allosteric modulation of the WD40-repeat class of proteins.
Cullin-RING ligases are one of the largest families of E3 ubiquitin ligases and provide specificity to E1-E2-E3 ubiquitin transfer cascades. The typical cullin-RING ligase-a
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Two studies show that specific cullin-RING E3 ubiquitin ligases can be targeted with small molecules.
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